Background

Pregnancy is a process characterized by rapid and profound physiological changes throughout the maternal system. The cardiovascular, metabolic, and immune systems must dynamically adapt to support fetal growth, ultimately leading to a healthy outcome. However, the genetic mechanisms regulating these physiological changes during pregnancy remain largely unknown. Previous genome-wide association studies (GWAS) have primarily focused on non-pregnant adults and have been limited by their reliance on single-time-point data during pregnancy. Conducting longitudinal studies with large cohorts of pregnant women and data collection throughout the entire gestational period poses significant logistical and financial challenges. To address these challenges, researchers propose an alternative approach: repurposing high-resolution genome sequencing data generated during non-invasive prenatal testing (NIPT). NIPT is a routine screening test that analyzes cell-free DNA in maternal blood to detect fetal chromosomal abnormalities. By linking the genetic data obtained from this test with clinical records, a large cohort can be effectively established. The researchers used this approach to elucidate the dynamic hormonal changes and metabolic processes that occur during pregnancy.

Key Findings

The researchers conducted a comprehensive analysis, linking genomic information from up to 121,579 Chinese pregnant women with data on 111 clinical phenotypes. These phenotypes include lipid and glucose metabolism markers, blood cell parameters, and pregnancy complications. The analysis identified thousands of independent genetic loci associated with physiological traits during pregnancy. A significant proportion of these genetic regions represent novel findings not previously reported in pregnancy-related traits. A particularly noteworthy discovery is the identification of dynamic genetic effects that vary across gestational weeks. Analysis of blood parameters measured repeatedly during pregnancy revealed that approximately 18% of the overall genetic signal exhibits interactions with gestational week, resulting in changes in effect size. Specific genetic variants demonstrate strong effects on maternal blood cell counts early in pregnancy, but these effects diminish or reverse later in pregnancy. These time-specific genes are strongly enriched in biological pathways involved in hormone response, immune regulation, and fetal growth. Furthermore, Mendelian randomization (MR) analysis was used to investigate the causal relationship between physiological abnormalities during pregnancy and the risk of chronic diseases in mothers after delivery. The results indicate that disruptions in metabolic markers during pregnancy are directly associated with an increased risk of cardiovascular disease and type 2 diabetes in mothers in the long term.

Significance and Implications

This research redefines pregnancy not as a static physiological state, but as a dynamic process of continuous genetic regulation. It supports the need to move beyond simply applying existing adult research findings to pregnant women and instead establish a dedicated genomic reference for pregnant women. Moreover, the study demonstrates a new paradigm for healthcare data utilization by repurposing NIPT data, which is typically used for a single-time-point test, into a valuable resource for research. The study demonstrates the feasibility of leveraging existing healthcare infrastructure to create a large, high-quality genomic cohort of 120,000 individuals. However, some limitations should be acknowledged. This study focused solely on Chinese pregnant women, and further validation is needed to determine whether the same effects are observed in other ethnic groups. Additionally, the analysis was based on data collected at a limited number of time points during NIPT, and future studies should incorporate long-term follow-up data after delivery.

Why It Matters

This research has the potential to be used as a precision medicine tool for personalized pregnancy management in the clinical setting. For example, during routine NIPT screening in early pregnancy, the fetal screening can be combined with an analysis of the mother's genomic information. This analysis can be used to calculate the risk of developing high-risk complications such as gestational diabetes and preeclampsia later in pregnancy, based on the individual mother's genetic profile and gestational week-specific prediction curves. Based on these predictions, healthcare providers can prescribe proactive dietary adjustments or design personalized clinical management plans to prevent complications. From an industrial perspective, this research is expected to change the paradigm of the existing NIPT screening market. Diagnostic companies are likely to expand their business areas from simple fetal abnormality detection to comprehensive healthcare solutions that cover the mother's entire lifespan. Given that the causal relationship between gestational metabolic diseases and chronic diseases after delivery has been genetically elucidated, research to identify new therapeutic targets in the development of female-targeted drugs is also expected to accelerate.